Credit Suisse Group set a $80.00 price target on Eli Lilly and (NYSE:LLY) in a report published on Sunday morning. The brokerage currently has a hold rating on the stock.

Several other equities analysts have also recently weighed in on LLY. Jefferies Group set a $90.00 price target on shares of Eli Lilly and and gave the stock a buy rating in a research note on Friday, April 13th. BMO Capital Markets raised Eli Lilly and from an underperform rating to a market perform rating and increased their price objective for the company from $74.00 to $79.00 in a report on Friday, April 13th. They noted that the move was a valuation call. HC Wainwright reissued a buy rating on shares of Eli Lilly and in a report on Wednesday, April 18th. Zacks Investment Research raised Eli Lilly and from a hold rating to a buy rating and set a $87.00 price objective for the company in a report on Wednesday, April 11th. Finally, Bank of America cut their price objective on Eli Lilly and from $88.00 to $86.00 and set a neutral rating for the company in a report on Thursday, February 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $93.16.

Shares of LLY opened at $79.06 on Friday. The company has a market cap of $86,617.97, a PE ratio of 18.47, a price-to-earnings-growth ratio of 1.44 and a beta of 0.26. Eli Lilly and has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $0.95 EPS. sell-side analysts expect that Eli Lilly and will post 4.88 EPS for the current fiscal year.

In other news, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the sale, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Susan Mahony sold 5,165 shares of Eli Lilly and stock in a transaction on Friday, April 13th. The stock was sold at an average price of $80.14, for a total value of $413,923.10. Following the sale, the senior vice president now directly owns 45,652 shares of the company’s stock, valued at approximately $3,658,551.28. The disclosure for this sale can be found here. Insiders have sold 42,970 shares of company stock valued at $3,444,557 in the last three months. Insiders own 0.11% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Eli Lilly and by 6.9% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 106,014 shares of the company’s stock worth $8,954,000 after buying an additional 6,830 shares in the last quarter. Colonial Trust Advisors increased its position in shares of Eli Lilly and by 35.0% in the fourth quarter. Colonial Trust Advisors now owns 65,467 shares of the company’s stock worth $5,529,000 after purchasing an additional 16,973 shares during the period. Xact Kapitalforvaltning AB increased its position in shares of Eli Lilly and by 7.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 200,443 shares of the company’s stock worth $16,929,000 after purchasing an additional 14,586 shares during the period. Handelsbanken Fonder AB increased its position in shares of Eli Lilly and by 2.7% in the fourth quarter. Handelsbanken Fonder AB now owns 309,140 shares of the company’s stock worth $26,110,000 after purchasing an additional 8,200 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in shares of Eli Lilly and by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 224,857 shares of the company’s stock worth $18,991,000 after purchasing an additional 7,162 shares during the period. 77.69% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/04/23/eli-lilly-and-lly-given-a-80-00-price-target-at-credit-suisse-group.html.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.